HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS

Current HIV Research

Volumn 9, Issue 3, 2011, Pages 148-153

  d'Ettorre, Gabriella ^a   Paiardini, Mirko ^b   Zaffiri, Lorenzo ^a   Andreotti, Mauro ^c   Ceccarelli, Giancarlo ^a   Rizza, Cecilia ^a   Indinnimeo, Marileda ^a   Vella, Stefano ^c   Mastroianni, Claudio M ^a   Silvestri, Guido ^b   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b EMORY UNIVERSITY   (United States)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Gut; HIV; HIV DNA; Immune activation; LPS; Virus persistence

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; LIPOPOLYSACCHARIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MALE; MICROBIAL KINETICS; MICROBIAL TRANSLOCATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD38; ANTIGENS, CD8; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL TRANSLOCATION; DNA, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PLASMA; T-LYMPHOCYTE SUBSETS;

EID: 79957880036     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016211795945296     Document Type: Article

References (31)

1. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231-41.
2. Lane HC. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010; 18: 2-6.
3. Fernandez S, Lim A, French M. Immune activation and the pathogenesis of HIV disease: implications for therapy. J HIV Ther 2009; 14: 52-56.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
5. Valdez H. Immune restoration after treatment of HIV-1 infection with highly active antiretroviral therapy (HAART). AIDS Rev 2002; 4: 157-64.
6. Jiménez A, Molero L, Jiménez A, et al. Role of antiretroviral regimes in HIV-1 patients in reducing immune activation. Immunology 2002; 106: 80-6.
7. Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol 2007; 179: 2642-50.
8. Soudeyns H, Campi G, Rizzardi GP, et al. Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. Blood 2000; 95: 1743-51.
9. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-55.
10. Fleury S, Rizzardi GP, Chapuis A, et al. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97: 5393-8.
11. Rong L, Perelson AS. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIVinfected patients on potent therapy. PLoS Comput Biol 2009; 5: e1000533.
12. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83: 8470-81.
13. Ciccone EJ, Read SW, Mannon PJ, et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol 2010; 3: 172-81.
14. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Michau C, Kerdraon R, Agoute E, Rouzioux C. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 2008; 22: 1880-2.
15. Belmonte L, Olmos M, Fanin A, et al. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. AIDS 2007; 21: 2106-8.
16. Lackner AA, Mohan M, Veazey RS. The gastrointestinal tract and AIDS pathogenesis. Gastroenterology 2009; 136: 1965-78.
17. Ortiz AM, Silvestri G. Immunopathogenesis of AIDS. Curr Infect Dis Rep 2009; 11: 239-45.
18. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
19. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10: 36-46.
20. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1: 23-30.
21. Ng SC, Gazzard B. Advances in sexually transmitted infections of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2009; 6: 592-607.
22. Brenchley JM, Douek, DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS 2008; 3: 356-61.
23. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007; 4: 10-15.
24. Wallet MA, Rodriguez CA, Yin L, etal. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24: 1281-90.
25. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-84.
26. Ford ES, Puronen CE, Sereti I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS 2009; 4: 206-14.
27. Silvestri G. AIDS pathogenesis: a tale of two monkeys. J Med Primatol 2008; 37 (Suppl 2): 6-12.
28. Cadogan M, Dalgleish AG. HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis 2008; 8: 675-84.
29. Savarino A, Bottarel F, Malavasi F, et al. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14, 1079-89.
30. d'Ettorre G, Zaffiri L, Ceccarelli G, et al. The role of HIV-DNA testing in clinical practice. New Microbiol 2010; 33: 1-11.
31. Beloukas A, Paraskevis D, Psichogiou M, Hatzakis A. The role of HIV-1 DNA as an additional marker of HIV-1 infection. Curr HIV Res 2009; 7: 255-65.